Kao WY, et al. - Using data from the Taiwan National Health Insurance Research Database for the period between 2003 and 2013, researchers explored the link between proton pump inhibitors (PPIs) use and hepatocellular carcinoma (HCC) risk. Thirty-five thousand, three hundred fifty-six patients with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections were identified. Among patients with chronic HBV or HCV infections, PPI use was not correlated with the risk of developing HCC.